32949-41-0

Usage

Uses

Used in Pharmaceutical Research:
(S)-2-((S)-2-benzyloxycarbonylamino-3-phenyl-propionylamino)-5-guanidinopentanoic acid is used as a therapeutic agent for various diseases and medical conditions. Its specific peptide sequence and guanidino functionality contribute to its potential in drug development and research into physiological processes.
Used in Biochemical Research:
In the field of biochemistry, (S)-2-((S)-2-benzyloxycarbonylamino-3-phenyl-propionylamino)-5-guanidinopentanoic acid serves as a valuable molecule for studying the interactions and mechanisms of various biological systems. Its unique structure allows researchers to explore its potential applications in understanding and modulating biological functions.
Used in Drug Development:
(S)-2-((S)-2-benzyloxycarbonylamino-3-phenyl-propionylamino)-5-guanidinopentanoic acid is also utilized in drug development due to its potential as a therapeutic agent. Its specific geometric arrangement and functional groups make it an attractive candidate for the design and synthesis of novel drugs targeting various diseases and medical conditions.

Upstream product

• 74-79-3 L-arginine 
• 17543-49-6 (S)-benzyloxycarbonylphenylalanine pentafluorophenyl ester 
• 769922-77-2 (S)-benzyl (1-(1H-benzo[d][1,2,3]triazol-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 170713-34-5 C₃₃H₃₆N₆O₆ 
• 3397-32-8 N-(benzyloxycarbonyl)-phenylalanine-N-hydroxysuccinimide ester 

Downstream Products

• 1238-09-1 L-phenylalanyl-L-arginine 
• 119439-70-2 C₅₈H₉₅N₁₇O₁₉S 
• 119459-99-3 (S)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-tert-butoxy-propionylamino)-3-phenyl-propionylamino]-5-guanidino-pentanoic acid 
• 119460-00-3 (S)-2-{(S)-2-[(S)-3-tert-Butoxy-2-((S)-2-tert-butoxycarbonylamino-3-carbamoyl-propionylamino)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid 
• 125510-00-1 (S)-2-[(S)-2-((S)-2-{(S)-2-[(S)-3-(Acetylamino-methylsulfanyl)-2-amino-propionylamino]-3-carbamoyl-propionylamino}-3-hydroxy-propionylamino)-3-phenyl-propionylamino]-5-guanidino-pentanoic acid 
• 119460-01-4 (S)-2-[(S)-2-((S)-2-{(S)-2-[(S)-3-(Acetylamino-methylsulfanyl)-2-tert-butoxycarbonylamino-propionylamino]-3-carbamoyl-propionylamino}-3-hydroxy-propionylamino)-3-phenyl-propionylamino]-5-guanidino-pentanoic acid 
• 74-79-3 L-arginine 
• 1161-13-3 N-Cbz-L-Phe 
• 195521-93-8 Z-Ala-Phe-Arg-OH 
• 116685-18-8 Ala-Phe-Arg 
• 195522-05-5 Boc-Cys(Acm)-Ala-Phe-Arg-Gln-Val-Cys(Acm)-NHEt 
• 195521-95-0 Boc-Cys(Acm)-Ala-Phe-Arg-OH 
• 803706-22-1 Z-Asp(OBzl)-Phe-Arg-OH 

Relevant academic research and scientific papers

Bottom-Up Construction of an Adaptive Enzymatic Reaction Network

The reproduction of emergent behaviors in nature using reaction networks is an important objective in synthetic biology and systems chemistry. Herein, the first experimental realization of an enzymatic reaction network capable of an adaptive response is reported. The design is based on the dual activity of trypsin, which activates chymotrypsin while at the same time generating a fluorescent output from a fluorogenic substrate. Once activated, chymotrypsin counteracts the trypsin output by competing for the fluorogenic substrate and producing a non-fluorescent output. It is demonstrated that this network produces a transient fluorescent output under out-of-equilibrium conditions while the input signal persists. Importantly, in agreement with mathematical simulations, we show that optimization of the pulse-like response is an inherent trade-off between maximum amplitude and lowest residual fluorescence.

Efficient synthesis of peptides by extension at the N- and C-terminii of arginine

(Chemical Equation Presented) L-Nω-Nitroarginine and L-arginine were coupled with N-(Cbz-α-aminoacyl)benzotriazoles and N-Cbz-dipeptidoylbenzotriazoles to provide arginine LL-dipeptides 9a-e, 11a-d; LLL-tripeptides 18a-c, 20; and diastereomeric mixtures (9b+9b′), (9c+9c′), (11b+11b′) and (18c+18c′) [compound numbers written within parentheses represent a diastereomeric mixture or racemate; compound numbers without parentheses represent an achiral compound or a single enantiomer] by extension at the N-terminus of arginine, in isolated yields of 66-95% with complete retention of chirality as evidenced by NMR and HPLC analysis. Arginine LL-dipeptides 15a-d were synthesized by extension at the C-terminus of arginine in isolated yield of 66-80%, using benzotriazole activated arginine L-ωNO2-Arg-Bt, 13. Our methodology has also been used to synthesize the protected RGD peptide (Cbz α-L-ωNO2-Arg-Gly-L-Asp-(OH) 2) 21.

Dipeptidyl-α,β-epoxyesters as potent irreversible inhibitors of the cysteine proteases cruzain and rhodesain

The dipeptidyl epoxyesters 3 and 4 are potent, irreversible inhibitors of cruzain and rhodesain.

Trends in asymmetric Michael reactions catalysed by tripeptides in combination with an achiral additive in different solvents

The potential of tripeptides 3, 6 and 12 as chiral catalysts for asymmetric Michael addition reactions in the presence of an achiral additive has been tested in different solvents (CHCI3, acetone, DMF, DMSO and the room-temperature ionic liquid

Synthesis of Ethylamide of Cyclic Undecapeptide Corresponding to the 593 - 603 Sequence of Transmembrane Glycoprotein gp41 of Human Immunodeficiency Virus Type Two

Ethylamide of cyclic disulfide of the HIV-2 peptide antigen corresponding to the 593 - 603 sequence of the gp41 protein was synthesized by conventional methods of peptide chemistry in solution.The absence of racemization during fragment condensation was s